Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018
RNA Sequencing-Based Platform Will Provide Extensive Genomic Content to Help Inform Surgery and Treatment Decisions for Patients with Suspected Thyroid Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that its soon-to-be-launched
Toggle Summary Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at ENDO 2018, the annual meeting of the Endocrine Society , suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more patients avoid


Date Event Details
Summary Toggle Sep 8, 2016 11:00 AM EDT
Veracyte Percepta Medicare Coverage Conference Call
Summary Toggle Nov 29, 2016 3:30 PM EST
Piper Jaffray 28th Annual Healthcare Conference


Title Documents

Veracyte Corporate Presentation, February 2018